Correlation Engine 2.0
Clear Search sequence regions


  • bone density (6)
  • calcium (1)
  • cellular (1)
  • denosumab (1)
  • exercises (1)
  • humans (1)
  • osteoporosis (4)
  • patients (1)
  • vitamin d (2)
  • weight (1)
  • Sizes of these terms reflect their relevance to your search.

    Osteoporosis is a skeletal condition characterized by decreased bone mineral density and poor bone quality with resultant greater fracture risk. There has been a focus on bone mineral density deficiency, which is easily measured with dual-energy x-ray absorptiometry and managed with pharmaceutic medications. More recently, impaired bone quality independent of bone mineral density has been recognized as a potential cause of fragility fracture and poor bone healing. Many conditions lead to poor bone quality; the most common is vitamin D deficiency and others are genetic causes and other nutritional deficits. In addition, the cellular and molecular changes associated with osteoporosis are being investigated and are potential targets for treatment. Treatment of patients with poor bone health include nutritional supplementation with vitamin D and calcium, weight-bearing exercises, and antiosteoporotic medications when warranted. Antiosteoporotic medications include antiresorptive drugs such as diphosphonate and denosumab that inhibit osteoclastic bone resorption. Anabolic agents such as teriparatide, abaloparatide, and romosozumab stimulate osteoblastic differentiation and bone formation. All these agents are effective in reducing fracture risk.

    Citation

    John R Dimar, Joseph M Lane, Ronald A Lehman, Paul A Anderson. The Basics of Bone Physiology, Healing, and Osteoporosis. Instructional course lectures. 2021;70:527-536

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33438933

    View Full Text